Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables Refunds
Ratios

Keros Therapeutics (KROS) Leases (2019 - 2025)

Keros Therapeutics' Leases history spans 7 years, with the latest figure at $16.8 million for Q4 2025.

  • For Q4 2025, Leases fell 12.52% year-over-year to $16.8 million; the TTM value through Dec 2025 reached $16.8 million, down 12.52%, while the annual FY2025 figure was $16.8 million, 12.52% down from the prior year.
  • Leases reached $16.8 million in Q4 2025 per KROS's latest filing, down from $17.5 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $19.8 million in Q3 2024 to a low of $447000.0 in Q3 2022.
  • Average Leases over 5 years is $10.5 million, with a median of $15.2 million recorded in 2023.
  • Peak YoY movement for Leases: crashed 36.14% in 2022, then surged 3405.37% in 2023.
  • A 5-year view of Leases shows it stood at $1.1 million in 2021, then skyrocketed by 1343.3% to $15.4 million in 2022, then fell by 0.43% to $15.3 million in 2023, then rose by 25.54% to $19.3 million in 2024, then fell by 12.52% to $16.8 million in 2025.
  • Per Business Quant, the three most recent readings for KROS's Leases are $16.8 million (Q4 2025), $17.5 million (Q3 2025), and $18.1 million (Q2 2025).